Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,737 | 184 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $691.73 | 27 | $0 (2023) |
| Novo Nordisk Inc | $572.50 | 26 | $0 (2023) |
| ABBVIE INC. | $406.84 | 22 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $199.26 | 12 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $193.23 | 8 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $188.40 | 9 | $0 (2023) |
| GlaxoSmithKline, LLC. | $174.93 | 9 | $0 (2023) |
| Amgen Inc. | $171.36 | 10 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $148.99 | 9 | $0 (2020) |
| Kowa Pharmaceuticals America, Inc. | $148.69 | 7 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $20.17 | 1 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) ($20.17) |
| 2023 | $506.89 | 22 | PFIZER INC. ($187.51) |
| 2022 | $867.47 | 39 | PFIZER INC. ($267.22) |
| 2021 | $1,132 | 57 | PFIZER INC. ($163.44) |
| 2020 | $660.37 | 35 | AbbVie Inc. ($117.28) |
| 2019 | $226.55 | 11 | AbbVie, Inc. ($60.94) |
| 2018 | $195.80 | 11 | AstraZeneca Pharmaceuticals LP ($83.79) |
| 2017 | $127.95 | 8 | GlaxoSmithKline, LLC. ($55.11) |
All Payment Transactions
184 individual payment records from CMS Open Payments — Page 8 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/12/2018 | Takeda Pharmaceuticals U.S.A., Inc. | Trintellix (Drug) | Food and Beverage | In-kind items and services | $12.91 | General |
| Category: Central Nervous System (CNS) | ||||||
| 11/17/2017 | Allergan Inc. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $10.67 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/16/2017 | GlaxoSmithKline, LLC. | ADVAIR (Drug), FLOVENT | Food and Beverage | In-kind items and services | $23.08 | General |
| Category: RESPIRATORY | ||||||
| 08/25/2017 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $19.65 | General |
| 08/11/2017 | Takeda Pharmaceuticals America, Inc. | Trintellix (Drug) | Food and Beverage | In-kind items and services | $12.93 | General |
| Category: Central Nervous System (CNS) | ||||||
| 08/07/2017 | GlaxoSmithKline, LLC. | ADVAIR (Drug), FLOVENT | Food and Beverage | In-kind items and services | $18.59 | General |
| Category: RESPIRATORY | ||||||
| 05/12/2017 | AstraZeneca Pharmaceuticals LP | BEVESPI AEROSPHERE (Drug) | Food and Beverage | In-kind items and services | $16.74 | General |
| Category: Respiratory | ||||||
| 04/21/2017 | Mannkind Corporation | AFREZZA (Drug) | Food and Beverage | In-kind items and services | $12.85 | General |
| Category: DIABETES MEDICINE | ||||||
| 02/15/2017 | GlaxoSmithKline, LLC. | ADVAIR (Drug), FLOVENT | Food and Beverage | In-kind items and services | $13.44 | General |
| Category: RESPIRATORY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 186 | 206 | $31,050 | $12,346 |
| 2022 | 7 | 407 | 487 | $75,845 | $31,403 |
| 2021 | 8 | 371 | 430 | $69,942 | $30,737 |
| 2020 | 9 | 463 | 533 | $86,218 | $35,879 |
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 32 | 38 | $11,025 | $4,899 | 44.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 28 | 28 | $11,175 | $4,154 | 37.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 24 | 31 | $4,380 | $1,883 | 43.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 21 | 24 | $1,890 | $586.49 | 31.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 52 | 56 | $840.00 | $470.40 | 56.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 29 | 29 | $1,740 | $352.93 | 20.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 80 | 80 | $30,000 | $13,975 | 46.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 59 | 79 | $21,725 | $10,336 | 47.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 24 | 35 | $4,900 | $2,479 | 50.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 16 | 22 | $4,400 | $2,118 | 48.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 42 | 53 | $7,950 | $1,256 | 15.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 77 | 80 | $4,800 | $829.02 | 17.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 109 | 138 | $2,070 | $409.17 | 19.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 75 | 75 | $28,125 | $13,841 | 49.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 57 | 75 | $20,625 | $10,141 | 49.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 20 | 24 | $4,800 | $2,275 | 47.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 18 | 30 | $4,200 | $1,880 | 44.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 42 | 48 | $6,215 | $1,253 | 20.2% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 69 | 71 | $4,260 | $847.44 | 19.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 78 | 95 | $1,417 | $285.00 | 20.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 12 | 12 | $300.00 | $215.28 | 71.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 105 | 105 | $39,375 | $17,806 | 45.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 50 | 66 | $18,150 | $7,312 | 40.3% |
| 99354 | Prolonged office or other outpatient service first hour | Office | 2020 | 44 | 53 | $12,190 | $5,655 | 46.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 19 | 26 | $5,200 | $1,964 | 37.8% |
About Dr. Stasia Richter, M.D
Dr. Stasia Richter, M.D is a Internal Medicine healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/23/2005. The National Provider Identifier (NPI) number assigned to this provider is 1508869744.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stasia Richter, M.D has received a total of $3,737 in payments from pharmaceutical and medical device companies, with $20.17 received in 2024. These payments were reported across 184 transactions from 30 companies. The most common payment nature is "Food and Beverage" ($3,737).
As a Medicare-enrolled provider, Richter has provided services to 1,427 Medicare beneficiaries, totaling 1,656 services with total Medicare billing of $110,365. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Location Chicago, IL
- Active Since 05/23/2005
- Last Updated 09/08/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1508869744
Products in Payments
- ELIQUIS (Drug) $367.95
- Ozempic (Drug) $238.97
- Rybelsus (Drug) $180.33
- EVENITY (Biological) $171.36
- ENTRESTO (Drug) $163.66
- TRINTELLIX (Drug) $163.36
- Livalo (Drug) $148.69
- PREVNAR 20 (Biological) $144.82
- STIOLTO RESPIMAT (Drug) $144.73
- CREON (Drug) $135.81
- XIFAXAN (Drug) $132.93
- LINZESS (Drug) $116.41
- ADVAIR (Drug) $114.81
- Dayvigo (Drug) $97.55
- PREMARIN (Drug) $88.14
- NURTEC ODT (Drug) $84.03
- CHANTIX (Drug) $73.56
- Linzess (Drug) $71.34
- FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE (Biological) $49.80
- TRULICITY (Drug) $49.51
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Chicago
Dr. Myles Wolf, Md, MD
Internal Medicine — Payments: $1.8M
Dr. Merle Diamond, Md, MD
Internal Medicine — Payments: $1.4M
Dr. Elizabeth Kiracofe, M.d, M.D
Internal Medicine — Payments: $1.2M
Robert Kushner, Md, MD
Internal Medicine — Payments: $549,886
Dr. Adam Stein, M.d, M.D
Internal Medicine — Payments: $503,325
Devalingam Mahalingam, M.d, M.D
Internal Medicine — Payments: $501,247